[en] Full text: Selective arterial radioembolization of tumours has been shown to be an effective method of radionuclide therapy. But so far particles labelled with a short-lived beta-emitter are not available as an approved radiopharmaceutical in Europe. Therefore, labelling with ¹⁸⁸Re was performed for B-20 (HSA microspheres, 15-30 μm), MAA (HSA macroaggregates, 10-100 μm), Ultra Drivalon (polyvinyl-formaldehyde foam particles, 50-150 μm), Bio-Rex 70 resin (macroreticular-acrylic resin particles, 45-75 μm), Macro Prep High Q (methacrylate particles, 50 μm) and Angiostat (collagen particles, 1-15 μm). About 370 MBq of ¹⁸⁸Re-sodium perrhenate (2 ml) were mixed with 6 mg gentisic acid, 7.5 mg of SnCl₂-2H₂O and 0.5-5 mg of the respective particles in a glass vial. The suspension was boiled and shaken for 1 h (100 deg C). The particle preparations were washed twice after centrifugation. The final preparation for injection was found to be stable for all preparations up to 48 h after incubation with human plasma. The in-vivo stability was investigated 48 h after intravenous injection in 3-4 Wistar rats for each particle preparation using the lung as a model of a well perfused tumour. The release of activity from the lungs representing the metabolic destruction and the biological half-life (T_B1/2) were determined from whole-body scintigrams after 10 min, 1 h, 3 h, 6 h, 24 h and 48 h p.i. Successful labelling of different types of particles could be demonstrated. The most promising particles seems to be B-20 microspheres